Male Infertility Market 2020 - 2027

Table of Content

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Test
1.1.2 Treatment
1.1.3 Regional Scope
1.1.4 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity flow analysis (Model 1)
1.6.2 Volume price analysis (model 2)
1.7 List of Secondary Sources
1.8 Objectives
1.8.1 Objective - 1
1.8.2 Objective - 2
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.2.1 Test
2.2.2 Treatment
2.2.3 Region
2.3 Competitive Insights
2.4 Male Infertility Market Outlook, 2019
Chapter 3 Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Market Segmentation
3.3 Penetration & Growth Prospect Mapping
3.3.1 Penetration Analysis
3.3.2 Market driver analysis
3.3.2.1 High Adoption of Assisted Reproductive Technology (ART)
3.3.2.2 Increasing incidence of infertility
3.3.2.3 Acquisitions, mergers, and partnerships in the market
3.3.2.4 Technological advancements
3.3.3 Market restraint analysis
3.3.3.1 High cost of treatment
3.4 Male Infertility Market: Business Environment Analysis Tools
3.4.1 Porter’s Five Forces Analysis
3.4.2 PESTEL Analysis
3.5 Clinical Trial Analysis
Chapter 4 Male Infertility Market: Test Analysis
4.1 Male Infertility Test Market Share Analysis, 2019 & 2027
4.2 Male Infertility Test Market: Segment Dashboard:
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2027 for the Test Segment
4.3.1 DNA Fragmentation Technique
4.3.1.1 DNA fragmentation technique market, 2015 - 2027 (USD Million)
4.3.2 Oxidative Stress Analysis
4.3.2.1 Oxidative stress analysis market, 2015 - 2027 (USD Million)
4.3.3 Microscopic Examination
4.3.3.1 Microscopic Examination market, 2015 - 2027 (USD Million)
4.3.4 Sperm Agglutination
4.3.4.1 Sperm agglutination market, 2015 - 2027 (USD Million)
4.3.5 Computer Assisted Semen Analysis
4.3.5.1 Computer assisted semen analysis market, 2015 - 2027 (USD Million)
4.3.6 Sperm Penetration Assay
4.3.6.1 Sperm penetration assay market, 2015 - 2027 (USD Million)
4.3.7 Others
4.3.7.1 Others market, 2015 - 2027 (USD Million)
Chapter 5 Male Infertility Market: Treatment Analysis
5.1 Male Infertility Treatment Market Share Analysis, 2019 & 2027
5.2 Male Infertility Treatment Market: Segment Dashboard:
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2027 for the Treatment Segment
5.3.1 ART & Varicocele Surgery
5.3.1.1 ART & varicocele surgery market, 2015 - 2027 (USD Million)
5.3.2 Medication
5.3.2.1 Medication market, 2015 - 2027 (USD Million)
Chapter 6 Male Infertility Market: Regional Analysis
6.1 Male Infertility Regional Market Share Analysis, 2019 & 2027
6.2 Male Infertility Regional Market: Segment Dashboard
6.3 Regional Market Snapshot (Market Size, CAGR, Top Verticals, Key Players, Top Trends)
6.4 SWOT Analysis, by Region
6.4.1 North America
6.4.2 Europe
6.4.3 Asia Pacific
6.4.4 Latin America
6.4.5 MEA
6.5 Market Size, & Forecasts, and Trend Analysis, 2015 to 2027
6.5.1 North America
6.5.1.1 North America male infertility market, 2015 - 2027 (USD Million)
6.5.1.1.1 U.S.
6.5.1.1.1.1 Regulatory & reimbursement scenario
6.5.1.1.1.2 U.S. male infertility market, 2015 - 2027 (USD Million)
6.5.1.1.2 Canada
6.5.1.1.2.1 Regulatory & reimbursement scenario
6.5.1.1.2.2 Canada male infertility market, 2015 - 2027 (USD Million)
6.5.2 Europe
6.5.2.1 Europe male infertility market, 2015 - 2027 (USD Million)
6.5.2.1.1 U.K.
6.5.2.1.1.1 Regulatory & reimbursement scenario
6.5.2.1.1.2 U.K. male infertility market, 2015 - 2027 (USD Million)
6.5.2.1.2 Germany
6.5.2.1.2.1 Regulatory & reimbursement scenario
6.5.2.1.2.2 Germany male infertility market, 2015 - 2027 (USD Million)
6.5.3 Asia Pacific
6.5.3.1 Asia Pacific male infertility market, 2015 - 2027 (USD Million)
6.5.3.1.1 Japan
6.5.3.1.1.1 Regulatory & reimbursement scenario
6.5.3.1.1.2 Japan male infertility market, 2015 - 2027 (USD Million)
6.5.3.1.2 China
6.5.3.1.2.1 Regulatory & reimbursement scenario
6.5.3.1.2.2 China male infertility market, 2015 - 2027 (USD Million)
6.5.4 Latin America
6.5.4.1 Latin America male infertility market, 2015 - 2027 (USD Million)
6.5.4.1.1 Brazil
6.5.4.1.1.1 Regulatory & reimbursement scenario
6.5.4.1.1.2 Brazil male infertility market, 2015 - 2027 (USD Million)
6.5.4.1.2 Mexico
6.5.4.1.2.1 Regulatory & reimbursement scenario
6.5.4.1.2.2 Mexico male infertility market, 2015 - 2027 (USD Million)
6.5.5 Middle East and Africa (MEA)
6.5.5.1 MEA male infertility market, 2015 - 2027 (USD Million)
6.5.5.1.1 South Africa
6.5.5.1.1.1 Regulatory & reimbursement scenario
6.5.5.1.1.2 South Africa male infertility market, 2015 - 2027 (USD Million)
Chapter 7 Competitive Analysis
7.1 Strategic Framework/ Competition Categorization (Key innovators, Market leaders, emerging players
7.2 Vendor Landscape
7.2.1 Strategy Mapping
7.2.2 Launch of New Products
7.2.3 Merger and Acquisition
7.2.4 Product Approvals
7.3 Company Market Position Analysis (Geographic Presence, Product Portfolio, Strategic Initiatives)
7.4 Company Profiles
7.4.1 EMD Serono, Inc.
7.4.1.1 Company overview
7.4.1.2 Financial performance
7.4.1.3 Product benchmarking
7.4.1.4 Strategic initiatives
7.4.2 Endo International plc
7.4.2.1 Company overview
7.4.2.2 Financial performance
7.4.2.3 Product benchmarking
7.4.2.4 Strategic initiatives
7.4.2.5 SWOT analysis
7.4.3 Sanofi
7.4.3.1 Company overview
7.4.3.2 Financial performance
7.4.3.3 Product benchmarking
7.4.3.4 Strategic initiatives
7.4.3.5 SWOT Analysis
7.4.4 Bayer Group
7.4.4.1 Company overview
7.4.4.2 Financial performance
7.4.4.3 Product benchmarking
7.4.4.4 Strategic initiatives
7.4.4.5 SWOT analysis
7.4.5 SCSA Diagnostics
7.4.5.1 Company overview
7.4.5.2 Product benchmarking
7.4.6 Andrology Solutions
7.4.6.1 Company overview
7.4.6.2 Product benchmarking
7.4.7 Halotech DNA SL
7.4.7.1 Company overview
7.4.7.2 Product benchmarking
7.4.7.3 Strategic initiatives
7.4.8 Intas Pharmaceuticals Ltd.
7.4.8.1 Company overview
7.4.8.2 Financial performance
7.4.8.3 Product benchmarking
7.4.8.4 Strategic initiatives
7.4.8.5 SWOT analysis
7.4.9 Aytu BioScience, Inc.
7.4.9.1 Company overview
7.4.9.2 Financial performance
7.4.9.3 Product Benchmarking
7.4.9.4 Strategic initiatives
7.4.9.5 SWOT Analysis
7.4.10 Cadila Pharmaceuticals
7.4.10.1 Company overview
7.4.10.2 Product benchmarking
7.4.10.3 Strategic initiatives
7.4.11 Vitrolife
7.4.11.1 Company overview
7.4.11.2 Financial performance
7.4.11.3 Product benchmarking
7.4.11.4 Strategic initiatives
7.4.11.5 SWOT Analysis
Chapter 8 Recommendations